<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787616</url>
  </required_header>
  <id_info>
    <org_study_id>R15006</org_study_id>
    <nct_id>NCT02787616</nct_id>
  </id_info>
  <brief_title>Genetic Basis of Rosacea</brief_title>
  <official_title>Validation of Candidate Rosacea Genes By Targeted Interrogation of Alleles and Assessment of Rosacea Co-morbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Rosacea is a common disease characterized by inflammation and vascular abnormalities of the&#xD;
      facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well&#xD;
      understood and current methods to treat this disease are often unsatisfactory. The purpose of&#xD;
      this study is to develop gene expression profiles of papulopustular rosacea compared to those&#xD;
      of normal skin. The investigators hope to better understand the abnormal gene functions that&#xD;
      might contribute to this condition. This understanding may lead to the development of&#xD;
      additional and better treatments for rosacea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2012</start_date>
  <completion_date type="Actual">November 16, 2018</completion_date>
  <primary_completion_date type="Actual">November 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Targeted interrogation of alleles and assessment of rosacea co-morbidities.</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">306</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Rosacea Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Rosacea Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>buccal swab</intervention_name>
    <description>cheek swab for DNA sampling</description>
    <arm_group_label>Non-Rosacea Group</arm_group_label>
    <arm_group_label>Rosacea Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        300 individuals will be enrolled, 150 with dermatologist verified rosacea and 150 without&#xD;
        rosacea.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria for Rosacea Group:&#xD;
&#xD;
        Inclusion criteria for rosacea participants:&#xD;
&#xD;
          1. Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic&#xD;
             subtypes) present at enrollment as determined by the investigator&#xD;
&#xD;
          2. All four grandparents of European descent&#xD;
&#xD;
          3. Fitzpatrick skin type I or II&#xD;
&#xD;
          4. Age 18 years or older&#xD;
&#xD;
        Exclusion criteria for rosacea participants:&#xD;
&#xD;
          1. Unable or unwilling to provide written informed consent&#xD;
&#xD;
          2. Concomitant facial or medical condition that obscures diagnosis of rosacea (such as&#xD;
             malar erythema from lupus erythematosus)&#xD;
&#xD;
          3. Acne vulgaris&#xD;
&#xD;
          4. Unable or unwilling to provide peripheral blood sample (a few teaspoons)&#xD;
&#xD;
          5. Inability for investigator to verify rosacea diagnosis on clinical examination due to&#xD;
             rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser&#xD;
             treatments, systemic tetracycline usage, etc.)&#xD;
&#xD;
          6. Use of topical prescription medications or procedures to the face within one month of&#xD;
             enrollment&#xD;
&#xD;
          7. Women who are pregnant or lactating&#xD;
&#xD;
        Eligibility Criteria for Non-Rosacea Group:&#xD;
&#xD;
        Inclusion criteria for control participants:&#xD;
&#xD;
          1. No history of rosacea&#xD;
&#xD;
          2. No clinical signs or symptoms of rosacea&#xD;
&#xD;
          3. No family history of rosacea&#xD;
&#xD;
          4. All four grandparents of European descent&#xD;
&#xD;
          5. Fitzpatrick skin type I or II&#xD;
&#xD;
          6. Age 18 years or older&#xD;
&#xD;
        Exclusion criteria for control participants:&#xD;
&#xD;
          1. Unable or unwilling to provide written informed consent&#xD;
&#xD;
          2. Acne vulgaris&#xD;
&#xD;
          3. Unable or unwilling to provide peripheral blood sample (a few teaspoons)&#xD;
&#xD;
          4. Women who are pregnant or lactating&#xD;
&#xD;
          5. Use of topical prescription medications or procedures to the face within one month of&#xD;
             enrollment&#xD;
&#xD;
          6. Skin conditions that might interfere with interpretation of procedure results (at the&#xD;
             discretion of the investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Dermatology</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

